ClinicalTrials.gg
CompletedNCT02606305Updated Jun 14, 2024Results posted

Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer

A Phase 1/2 interventional study of Mirvetuximab soravtansine and Bevacizumab in Epithelial Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer, sponsored by ImmunoGen, Inc.. Completed at 12 sites in 4 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-14.

Sponsored by ImmunoGen, Inc. (part of AbbVie) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
264
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 500 studies in Carcinoma, Ovarian Epithelial with a site in United States — 29 open to participants now, 50 under way, 8 of them phase 3. Carcinoma, Ovarian Epithelial · United States.

Enrollment
41st of 381
264 · median 35
Started
2016
with 11 others
Phase 1/2
51 of 500
3 open now
Registered
397th of 500
by date

Among the 500 studies in Carcinoma, Ovarian Epithelial with a site in United States, this one is the 41st largest by enrollment of the 381 interventional ones that give a count, is one of 12 that started in 2016, is one of 51 in phase 1/2, and was the 397th registered.

Carcinoma, Ovarian Epithelial

798 studies on the registry are indexed under Carcinoma, Ovarian Epithelial; 102 are open to participants now.

Browse Carcinoma, Ovarian Epithelial studies →

Open to participants now

29 of the 500 studies in Carcinoma, Ovarian Epithelial with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 75 Carcinoma, Ovarian Epithelial studies recruiting now, 50 (67%) set no upper age limit and 12 (16%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 500 studies in Carcinoma, Ovarian Epithelial with a site in United States, or all of them as a file.
02

Study summary

This study comprises a Dose Escalation phase followed by a Dose Expansion phase. Dose Escalation part of the study will assess the safety and tolerability and determine the maximum tolerated dose (MTD) as the recommended Phase 2 (RP2D) dose for each regimen. Participants will be assigned to one of the 4 regimens in Dose Escalation phase: Regimen A: mirvetuximab soravtansine administered with bevacizumab; Regimen B: mirvetuximab soravtansine administered with carboplatin; Regimen C: mirvetuximab soravtansine administered with pegylated liposomal doxorubicin; or Regimen D: mirvetuximab soravtansine administered with pembrolizumab. Dose Expansion of the study will further assess safety, tolerability and preliminary anti-tumor activity of mirvetuximab soravtansine. A Dose Expansion phase is planned for Regimen A and Regimen D and will open pending Sponsor decision; participants enrolled in the Dose Expansion phase will receive study treatment at the MTD or RP2D determined during Dose Escalation. For Regimen A, participants in the Dose Expansion phase may be enrolled according to prior exposure to bevacizumab into 3 Dose Expansion Cohorts as follows: 1) Dose Expansion Cohort 1: bevacizumab naïve; 2) Dose Expansion Cohort 2: bevacizumab pretreated; and 3) Dose Expansion Cohort 3: one to three prior treatments, one of which could have been bevacizumab. A triplet Regimen (Regimen E: mirvetuximab soravtansine + bevacizumab + carboplatin) will be opened to evaluate the safety and tolerability and to assess any early signs of activity in participants dosed with the combination regimen. All mirvetuximab soravtansine doses were calculated according to adjusted ideal body weight.

Read the detailed description

Participants will continue to receive mirvetuximab soravtansine and/or the combination agent until progressive disease (PD), unacceptable toxicity, or withdrawal of consent, whichever comes first, or until the Sponsor terminates the study.

03

Conditions studied

  • Epithelial Ovarian Cancer
  • Primary Peritoneal Cancer
  • Fallopian Tube Cancer

Keywords

  • Epithelial ovarian cancer
  • Fallopian tube cancer
  • Primary peritoneal cancer
  • IMGN853
  • ADC
  • Antibody drug conjugate
  • ImmunoGen
  • Antibody
  • Phase 1
  • Folate receptor alpha
  • Mirvetuximab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with advanced epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer
  • Folate receptor α (FRα) positive tumor expression as defined in the protocol
  • Willing to provide an block or slides or undergo tumor biopsy. New tumor biopsy (Cycle 2 Day 8) is required for Regimen D.

Exclusion criteria

Exclusion Criteria:

  • Primary platinum- disease
  • Diagnosis of clear cell, low grade ovarian cancer or mixed tumors
  • Serious concurrent illness or active infection, including but not limited to known diagnosis of (HIV) and or C, as defined in the protocol
  • Active disease requiring systemic therapy in past 2 years (for Regimen D only)
  • Women who are pregnant or breastfeeding
  • Male participants
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
264 participants (actual)

Study arms

  • Experimental
    Regimen A (Mirvetuximab soravtansine + Bevacizumab)

    Mirvetuximab soravtansine + Bevacizumab administered on Day 1 of each 21-day cycle in Dose Escalation and Dose Expansion phase.

    Drug: Mirvetuximab soravtansine · Drug: Bevacizumab

  • Experimental
    Regimen B (Mirvetuximab soravtansine + Carboplatin)

    Mirvetuximab soravtansine + Carboplatin administered on Day 1 of each 21-day cycle in Dose Escalation phase.

    Drug: Mirvetuximab soravtansine · Drug: Carboplatin

  • Experimental
    Regimen C (Mirvetuximab soravtansine + Pegylated liposomal doxorubicin)

    Mirvetuximab soravtansine + Pegylated liposomal doxorubicin administered on Day 1 of each 28-day cycle in Dose Escalation Phase.

    Drug: Mirvetuximab soravtansine · Drug: Pegylated Liposomal Doxorubicin

  • Experimental
    Regimen D (Mirvetuximab soravtansine + Pembrolizumab)

    Mirvetuximab soravtansine + Pembrolizumab administered on Day 1 of each 21-day cycle in Dose Escalation and Dose Expansion phase.

    Drug: Mirvetuximab soravtansine · Drug: Pembrolizumab

  • Experimental
    Regimen E (Mirvetuximab soravtansine + Bevacizumab + Carboplatin)

    Mirvetuximab soravtansine + Bevacizumab + Carboplatin administered on Day 1 of each 21-day cycle in Dose Expansion phase.

    Drug: Mirvetuximab soravtansine · Drug: Bevacizumab · Drug: Carboplatin

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    Adverse events (AEs) were any noxious, pathologic, or unintended change in anatomical, physiologic, or metabolic function that developed or worsened during the clinical study, not necessarily having a causal relationship to study drug. Severity was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening, Grade 5=death. Serious AEs included death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized the participant and required medical intervention to prevent 1 of the outcomes previously listed. TEAEs were any AE that emerged on or after the first dose, and within 30 days of the last dose. Serious and other non-serious AEs regardless of causality are reported in the AE module.

    Time frame: From first dose of study drug up to 30 days after last dose of study drug (maximum exposure: 238.3 weeks)

  2. Dose Expansion (Regimens A and D) and Triplet (Regimen E): Objective Response Rate (ORR); Percentage of Participants With Confirmed Response, as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

    ORR was defined as percentage of participants with confirmed response (complete response \[CR\] + partial response \[PR\]). CR: Disappearance of all target or non-target lesions. All pathological or non-pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeters (mm). PR: At least 30 percent (%) decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline SLD. The 95% confidence interval (CI) was based on binomial distribution.

    Time frame: From first dose of study drug until first CR or PR (maximum exposure: 238.3 weeks)

Secondary outcomes

  1. Dose Escalation (Regimens A Through D): ORR; Percentage of Participants With Confirmed Response, as Assessed by RECIST Version 1.1

    ORR was defined as percentage of participants with confirmed response (CR + PR). CR: Disappearance of all target or non-target lesions. All pathological or non-pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least 30% decrease in the SLD of target lesions, taking as reference the baseline SLD.

    Time frame: From first dose of study drug until first CR or PR (maximum exposure: 238.3 weeks)

  2. Progression-Free Survival (PFS); Time From the Date Of First Dose Until The Date Of Progressive Disease (PD) Or Death By Any Cause, As Defined By RECIST Version 1.1

    PFS was defined as the time from the date of the first dose of study drug until the date of PD or death from any cause, whichever occurred first, estimated using the Kaplan-Meier method. PFS was defined based on radiological assessments and determined by the investigator. PD was defined as at least a 20% increase in the SLD of target lesions, taking as reference the smallest (nadir) SLD since and including baseline. In addition to the relative increase of 20%, the SLD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions and appearance of new lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.

    Time frame: From first dose of study drug until the date of PD or death by any cause (maximum exposure: 238.3 weeks)

  3. Duration of Response (DOR) Per RECIST v1.1 by Investigator Assessment

    DOR was defined as the time from the date of the first response (CR or PR), to the date of PD or death from any cause, whichever occurred first. DOR was only defined for patients who had a best overall response of CR or PR, estimated using the Kaplan-Meier method. The response-evaluable population included all patients with radiographic assessment at baseline, who received at least 1 dose of combination treatment and had at least 1 post-dose radiographic tumor assessment or who died within 105 days of first dose.

    Time frame: From the date of first objective response to the time of PD (maximum exposure: 238.3 weeks)

  4. Gynecologic Cancer Intergroup (GCIG) Cancer Antigen (CA)-125 Clinical Response Rate by Investigator Assessment

    A CA-125 response was defined as a ≥ 50% reduction in CA-125 levels from baseline. GCIG CA125 response rate was defined as the number of participants with a CA-125 confirmed response divided by the number of participants in the CA-125 response-evaluable population multiplied by 100. The CA-125 evaluable population included all participants whose pretreatment sample was ≥2.0 times the upper limit of normal, within 2 weeks prior to the first dose of combination treatment, and who had at least 1 post-baseline CA-125 evaluation.

    Time frame: From first dose of study drug until first CR or PR (maximum exposure: 238.3 weeks)

  5. Pharmacokinetics (PK) Parameter: Maximum Plasma Concentration (Cmax) of Mirvetuximab Soravtansine and Total Antibody

    Blood samples from participants were analyzed to characterize the PK of mirvetuximab soravtansine when administered in 3- or 4-week cycles. Results are reported in micrograms/milliliter (µg/mL).

    Time frame: Cycles 1 and 3: Day 1 (pre-infusion, within 10 minutes of end of infusion [EOI], and 6 hours post-infusion); Days 2 and 3 (24- and 48-hours post-infusion); Days 8 and 15 (additionally at Day 22 for Regimen C)

  6. PK Parameter: Cmax of N2'-[4-[(3-carboxypropyl)Dithio]-4-methyl-1-oxo-2-sulfopentyl]-N2'-Deacetylmaytansine (DM4) and S-methyl DM4 (SmDM4)

    Blood samples from participants were analyzed to characterize the PK of mirvetuximab soravtansine when administered in 3- or 4-week cycles. Results are reported in nanograms (ng)/mL.

    Time frame: Cycles 1 and 3: Day 1 (pre-infusion, within 10 minutes of end of infusion [EOI], and 6 hours post-infusion); Days 2 and 3 (24- and 48-hours post-infusion); Days 8 and 15 (additionally at Day 22 for Regimen C)

  7. PK Parameter: Area Under the Time-Concentration Curve From Time 0 To Infinite Time (AUCinf) of Mirvetuximab Soravtansine and Total Antibody

    Blood samples from participants were analyzed to characterize the PK of mirvetuximab soravtansine when administered in 3- or 4-week cycles. Results are reported in mg\*hours (h)/mL.

    Time frame: Cycles 1 and 3: Day 1 (pre-infusion, within 10 minutes of EOI, and 6 hours post-infusion); Days 2 and 3 (24- and 48-hours post-infusion); Days 8 and 15 (additionally at Day 22 for Regimen C)

  8. PK Parameter: AUCinf of Intact DM4 and SmDM4

    Blood samples from participants were analyzed to characterize the PK of mirvetuximab soravtansine when administered in 3- or 4-week cycles. Note that '9999' is used because AUCinf cannot be calculated for n\<3.

    Time frame: Cycles 1 and 3: Day 1 (pre-infusion, within 10 minutes of EOI, and 6 hours post-infusion); Days 2 and 3 (24- and 48-hours post-infusion); Days 8 and 15 (additionally at Day 22 for Regimen C)

  9. PK Parameter: Terminal Half-Life (t½) of Mirvetuximab Soravtansine, Total Antibody, DM4, and SmDM4

    Blood samples from participants were analyzed to characterize the PK of mirvetuximab soravtansine when administered in 3- or 4-week cycles. PK parameters were calculated using standard non-compartmental methods. The terminal t½ is an estimate (extrapolation) of the time it takes for the concentration or amount in the body of that drug to be reduced by exactly one-half (50%). If extrapolated AUC was greater than 20% (due to insufficient number of participants with data samples) the upper range of t½ was not reported.

    Time frame: Cycles 1 and 3: Day 1 (pre-infusion, within 10 minutes of EOI, and 6 hours post-infusion); Days 2 and 3 (24- and 48-hours post-infusion); Days 8 and 15 (up to 336 hours) (additionally at Day 22 for Regimen C)

  10. PK Parameter: Clearance (CL) of Mirvetuximab Soravtansine and Total Antibody

    Blood samples from participants were analyzed to characterize the PK of mirvetuximab soravtansine when administered in 3- or 4-week cycles.

    Time frame: Cycles 1 and 3: Day 1 (pre-infusion, within 10 minutes of EOI, and 6 hours post-infusion); Days 2 and 3 (24- and 48-hours post-infusion); Days 8 and 15 (additionally at Day 22 for Regimen C)

  11. PK Parameter: CL of DM4 and SmDM4

    Blood samples from participants were analyzed to characterize the PK of mirvetuximab soravtansine when administered in 3- or 4-week cycles.

    Time frame: Cycles 1 and 3: Day 1 (pre-infusion, within 10 minutes of EOI, and 6 hours post-infusion); Days 2 and 3 (24- and 48-hours post-infusion); Days 8 and 15 (additionally at Day 22 for Regimen C)

  12. PK Parameter: Volume of Distribution at Steady State (Vss) of Mirvetuximab Soravtansine, Total Antibody, DM4, and SmDM4

    Blood samples from participants were analyzed to characterize PK when administered in 3- or 4-week cycles.

    Time frame: Cycles 1 and 3: Day 1 (pre-infusion, within 10 minutes of EOI, and 6 hours post-infusion); Days 2 and 3 (24- and 48-hours post-infusion); Days 8 and 15 (additionally at Day 22 for Regimen C)

  13. PK Parameter: Time to Reach Cmax (Tmax) of Mirvetuximab Soravtansine, Total Antibody, DM4, and SmDM4

    Blood samples from participants were analyzed to characterize the PK of mirvetuximab soravtansine when administered in 3- or 4-week cycles. PK parameters were derived using non-compartmental PK analysis.

    Time frame: Cycles 1 and 3: Day 1 (pre-infusion, within 10 minutes of EOI, and 6 hours post-infusion); Days 2 and 3 (24- and 48-hours post-infusion); Days 8 and 15 (up to 336 hours) (additionally at Day 22 for Regimen C)

  14. Plasma Concentration of Bevacizumab

    Blood samples from participants at the end of infusion were analyzed to characterize the PK of mirvetuximab soravtansine when administered in 3- or 4-week cycles.

    Time frame: At end of infusion (EOI) of Cycle 1; and at pre-infusion and EOI of Cycles 2 to 6

  15. Plasma Concentration of Carboplatin

    Blood samples from participants at the end of infusion were analyzed to characterize the PK of mirvetuximab soravtansine when administered in 3- or 4-week cycles.

    Time frame: At end of infusion, 6 and 24 hours post-infusion of Cycle 1; and at pre-infusion and end of infusion of Cycles 2, 4, 5 and 6; at pre-infusion, end of infusion and 6 and 24 hours post-infusion of Cycle 3

  16. Plasma Concentration of Pegylated Liposomal Doxorubicin

    Blood samples from participants at the end of infusion were analyzed to characterize the PK of mirvetuximab soravtansine when administered in 3- or 4-week cycles.

    Time frame: At end of infusion of Cycle 1; and at pre-infusion and end of infusion of Cycles 2 to 6

  17. Immunogenicity: Number of Participants With Anti-Drug Antibody (ADA) Response to Mirvetuximab Soravtansine

    Blood samples were collected to measure the presence of ADAs for mirvetuximab soravtansine. Seronegative is defined as a participant that tests negative at all visits. Treatment-emergent ADA is defined as a participant that is seronegative prior to dosing on Day 1 of Cycle 1 and tests positive in both screening and confirmatory assays at one or more subsequent visits. Treatment-unaffected ADA is defined as a participant test positive in both screening and confirmatory assays prior to dosing on Day 1 of Cycle 1 with a post-dose titer increase of less than or equal to 4-fold (based on a 2-fold sample dilution). Treatment-boosted ADA is defined as a participant test positive in both screening and confirmatory assays prior to dosing on Day 1 of Cycle 1 with a post-dose titer increase of more than a 4-fold increase (based on a 2-fold sample dilution).

    Time frame: From first dose of study drug up to 30 days after last dose of study drug (maximum exposure: 283.3 weeks)

07

Results

Posted Feb 14, 2024

Participant flow

Dose Escalation: Regimens A, B, C and D
Participant flow — Dose Escalation: Regimens A, B, C and D
MilestoneRegimen A Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kgRegimen A Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kgRegimen A Dose Expansion Cohort 1: Bevacizumab-naïveRegimen A Dose Expansion Cohort 2: Bevacizumab Pre-treatedRegimen A Dose Expansion Cohort 3: Pt-agnostic:Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5Regimen B Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2Regimen C Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2Regimen D Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mgRegimen D Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mgRegimen D Dose Expansion: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mgRegimen E: Mirvetuximab Soravtansine + Bevacizumab + Carboplatin
Started311000441045741000
Received at least 1 dose of study drug311000441045741000
Completed311000441045741000
Not completed000000000000000
Dose Expansion: Regimens A and D
Participant flow — Dose Expansion: Regimens A and D
MilestoneRegimen A Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kgRegimen A Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kgRegimen A Dose Expansion Cohort 1: Bevacizumab-naïveRegimen A Dose Expansion Cohort 2: Bevacizumab Pre-treatedRegimen A Dose Expansion Cohort 3: Pt-agnostic:Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5Regimen B Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2Regimen C Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2Regimen D Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mgRegimen D Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mgRegimen D Dose Expansion: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mgRegimen E: Mirvetuximab Soravtansine + Bevacizumab + Carboplatin
Started0021346000000000460
Received at least 1 dose of study drug002134600000000000
Completed002134600000000000
Not completed0000000000000460
Triplet Dose: Regimen E
Participant flow — Triplet Dose: Regimen E
MilestoneRegimen A Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kgRegimen A Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kgRegimen A Dose Expansion Cohort 1: Bevacizumab-naïveRegimen A Dose Expansion Cohort 2: Bevacizumab Pre-treatedRegimen A Dose Expansion Cohort 3: Pt-agnostic:Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5Regimen B Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2Regimen C Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2Regimen D Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mgRegimen D Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mgRegimen D Dose Expansion: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mgRegimen E: Mirvetuximab Soravtansine + Bevacizumab + Carboplatin
Started0000000000000041
Received at least 1 dose of study drug0000000000000041
Completed0000000000000041
Not completed000000000000000

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

Adverse events (AEs) were any noxious, pathologic, or unintended change in anatomical, physiologic, or metabolic function that developed or worsened during the clinical study, not necessarily having a causal relationship to study drug. Severity was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03: Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening, Grade 5=death. Serious AEs included death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized the participant and required medical intervention to prevent 1 of the outcomes previously listed. TEAEs were any AE that emerged on or after the first dose, and within 30 days of the last dose. Serious and other non-serious AEs regardless of causality are reported in the AE module.

Time frame:
From first dose of study drug up to 30 days after last dose of study drug (maximum exposure: 238.3 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsMirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kgMirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kgMirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mgMirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mgMirvetuximab Soravtansine + Bevacizumab + Carboplatin
Any TEAE3126441044745641
SAEs24924312322517
Grade >=3 TEAEs28524723613037
PrimaryDose Expansion (Regimens A and D) and Triplet (Regimen E): Objective Response Rate (ORR); Percentage of Participants With Confirmed Response, as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

ORR was defined as percentage of participants with confirmed response (complete response \[CR\] + partial response \[PR\]). CR: Disappearance of all target or non-target lesions. All pathological or non-pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeters (mm). PR: At least 30 percent (%) decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline SLD. The 95% confidence interval (CI) was based on binomial distribution.

Time frame:
From first dose of study drug until first CR or PR (maximum exposure: 238.3 weeks)
Reported as:
Number · percentage of participants
Dose Expansion (Regimens A and D) and Triplet (Regimen E): Objective Response Rate (ORR); Percentage of Participants With Confirmed Response, as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
percentage of participantsRegimen A Dose Expansion Cohort 1: Bevacizumab-naïveRegimen A Dose Expansion Cohort 2: Bevacizumab Pre-treatedRegimen A Dose Expansion Cohort 3: Pt-agnostic:Regimen D Dose Expansion: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mgRegimen E: Mirvetuximab Soravtansine + Bevacizumab + Carboplatin
Dose Expansion (Regimens A and D) and Triplet (Regimen E): Objective Response Rate (ORR); Percentage of Participants With Confirmed Response, as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.152 (29.78 to 74.29)29 (15.10 to 47.48)50 (36.81 to 63.19)27 (14.60 to 41.94)83 (67.94 to 92.85)
SecondaryDose Escalation (Regimens A Through D): ORR; Percentage of Participants With Confirmed Response, as Assessed by RECIST Version 1.1

ORR was defined as percentage of participants with confirmed response (CR + PR). CR: Disappearance of all target or non-target lesions. All pathological or non-pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least 30% decrease in the SLD of target lesions, taking as reference the baseline SLD.

Time frame:
From first dose of study drug until first CR or PR (maximum exposure: 238.3 weeks)
Reported as:
Number · percentage of participants
Dose Escalation (Regimens A Through D): ORR; Percentage of Participants With Confirmed Response, as Assessed by RECIST Version 1.1
percentage of participantsRegimen A Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kgRegimen A Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kgRegimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5Regimen B Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2Regimen C Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2Regimen D Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mgRegimen D Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg
Dose Escalation (Regimens A Through D): ORR; Percentage of Participants With Confirmed Response, as Assessed by RECIST Version 1.10 (0.00 to 0.00)45 (16.75 to 76.62)50 (6.76 to 93.24)50 (6.76 to 93.24)89 (51.75 to 99.72)0 (0.00 to 0.00)20 (0.51 to 71.64)29 (3.67 to 70.96)25 (0.63 to 80.59)50 (18.71 to 81.29)
SecondaryProgression-Free Survival (PFS); Time From the Date Of First Dose Until The Date Of Progressive Disease (PD) Or Death By Any Cause, As Defined By RECIST Version 1.1

PFS was defined as the time from the date of the first dose of study drug until the date of PD or death from any cause, whichever occurred first, estimated using the Kaplan-Meier method. PFS was defined based on radiological assessments and determined by the investigator. PD was defined as at least a 20% increase in the SLD of target lesions, taking as reference the smallest (nadir) SLD since and including baseline. In addition to the relative increase of 20%, the SLD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions and appearance of new lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.

Time frame:
From first dose of study drug until the date of PD or death by any cause (maximum exposure: 238.3 weeks)
Reported as:
Median · months
Progression-Free Survival (PFS); Time From the Date Of First Dose Until The Date Of Progressive Disease (PD) Or Death By Any Cause, As Defined By RECIST Version 1.1
monthsRegimen A Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kgRegimen A Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kgRegimen A Dose Expansion Cohort 1: Bevacizumab-naïveRegimen A Dose Expansion Cohort 2: Bevacizumab Pre-treatedRegimen A Dose Expansion Cohort 3: Pt-agnostic:Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5Regimen B Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2Regimen C Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2Regimen D Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mgRegimen D Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mgRegimen D Dose Expansion: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mgRegimen E: Mirvetuximab Soravtansine + Bevacizumab + Carboplatin
Progression-Free Survival (PFS); Time From the Date Of First Dose Until The Date Of Progressive Disease (PD) Or Death By Any Cause, As Defined By RECIST Version 1.113.49 (11.76 to NA)8.80 (1.18 to NA)9.92 (7.13 to NA)6.77 (4.63 to 10.71)8.28 (6.34 to 11.01)13.52 (10.38 to NA)32.94 (10.38 to NA)16.46 (6.97 to NA)NA (1.68 to NA)7.03 (0.26 to NA)7.23 (1.45 to NA)2.53 (1.18 to NA)9.46 (1.38 to NA)4.17 (2.79 to 5.52)13.50 (9.86 to 16.30)
SecondaryDuration of Response (DOR) Per RECIST v1.1 by Investigator Assessment

DOR was defined as the time from the date of the first response (CR or PR), to the date of PD or death from any cause, whichever occurred first. DOR was only defined for patients who had a best overall response of CR or PR, estimated using the Kaplan-Meier method. The response-evaluable population included all patients with radiographic assessment at baseline, who received at least 1 dose of combination treatment and had at least 1 post-dose radiographic tumor assessment or who died within 105 days of first dose.

Time frame:
From the date of first objective response to the time of PD (maximum exposure: 238.3 weeks)
Reported as:
Median · months
Duration of Response (DOR) Per RECIST v1.1 by Investigator Assessment
monthsRegimen A Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kgRegimen A Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kgRegimen A Dose Expansion Cohort 1: Bevacizumab-naïveRegimen A Dose Expansion Cohort 2: Bevacizumab Pre-treatedRegimen A Dose Expansion Cohort 3: Pt-agnostic:Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5Regimen B Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2Regimen C Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2Regimen D Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mgRegimen D Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mgRegimen D Dose Expansion: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mgRegimen E: Mirvetuximab Soravtansine + Bevacizumab + Carboplatin
Duration of Response (DOR) Per RECIST v1.1 by Investigator Assessment—NA (2.76 to NA)11.96 (2.99 to NA)14.06 (3.91 to NA)10.38 (6.93 to 13.67)NA (6.05 to NA)31.77 (9.20 to NA)12.12 (4.40 to NA)—NA (NA to NA)NA (5.29 to NA)3.42 (NA to NA)8.31 (6.93 to NA)4.37 (2.79 to NA)10.87 (8.71 to 15.15)
SecondaryGynecologic Cancer Intergroup (GCIG) Cancer Antigen (CA)-125 Clinical Response Rate by Investigator Assessment

A CA-125 response was defined as a ≥ 50% reduction in CA-125 levels from baseline. GCIG CA125 response rate was defined as the number of participants with a CA-125 confirmed response divided by the number of participants in the CA-125 response-evaluable population multiplied by 100. The CA-125 evaluable population included all participants whose pretreatment sample was ≥2.0 times the upper limit of normal, within 2 weeks prior to the first dose of combination treatment, and who had at least 1 post-baseline CA-125 evaluation.

Time frame:
From first dose of study drug until first CR or PR (maximum exposure: 238.3 weeks)
Reported as:
Number · percentage of participants
Gynecologic Cancer Intergroup (GCIG) Cancer Antigen (CA)-125 Clinical Response Rate by Investigator Assessment
percentage of participantsRegimen A Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kgRegimen A Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kgRegimen A Dose Expansion Cohort 1: Bevacizumab-naïveRegimen A Dose Expansion Cohort 2: Bevacizumab Pre-treatedRegimen A Dose Expansion Cohort 3: Pt-agnostic:Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5Regimen B Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2Regimen C Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2Regimen D Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mgRegimen D Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mgRegimen D Dose Expansion: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mgRegimen E: Mirvetuximab Soravtansine + Bevacizumab + Carboplatin
Gynecologic Cancer Intergroup (GCIG) Cancer Antigen (CA)-125 Clinical Response Rate by Investigator Assessment100 (2.5 to 100.0)60 (26.2 to 87.8)75 (47.6 to 92.7)65 (44.3 to 82.8)71 (57.8 to 82.7)67 (9.4 to 99.2)100 (29.2 to 100.0)86 (42.1 to 99.6)0 (NA to NA)50 (1.3 to 98.7)50 (11.8 to 88.2)0 (NA to NA)63 (24.5 to 91.5)46 (29.5 to 63.1)100 (87.2 to 100.0)
SecondaryPharmacokinetics (PK) Parameter: Maximum Plasma Concentration (Cmax) of Mirvetuximab Soravtansine and Total Antibody

Blood samples from participants were analyzed to characterize the PK of mirvetuximab soravtansine when administered in 3- or 4-week cycles. Results are reported in micrograms/milliliter (µg/mL).

Time frame:
Cycles 1 and 3: Day 1 (pre-infusion, within 10 minutes of end of infusion [EOI], and 6 hours post-infusion); Days 2 and 3 (24- and 48-hours post-infusion); Days 8 and 15 (additionally at Day 22 for Regimen C)
Reported as:
Geometric mean · µg/mL
Pharmacokinetics (PK) Parameter: Maximum Plasma Concentration (Cmax) of Mirvetuximab Soravtansine and Total Antibody
µg/mLRegimen A Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kgRegimen A Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kgRegimen A Dose Expansion Cohort 1: Bevacizumab-naïveRegimen A Dose Expansion Cohort 2: Bevacizumab Pre-treatedRegimen A Dose Expansion Cohort 3: Pt-agnostic:Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5Regimen B Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2Regimen C Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2Regimen D Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mgRegimen D Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mgRegimen D Dose Expansion: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mgRegimen E: Mirvetuximab Soravtansine + Bevacizumab + Carboplatin
Mirvetuximab Soravtansine: Cycle 1135 ± 9.2137 ± 14.5159 ± 30.4159 ± 17.2150 ± 17.2118 ± 15.4108 ± 15.7144 ± 19.3115 ± 21.5114 ± 15.8146 ± 16.8112 ± 4156 ± 13.2151 ± 17.4144 ± 18.5
Mirvetuximab Soravtansine: Cycle 3NA ± NA148 ± 15.8164 ± 12.4174 ± 14.1137 ± 14446 ± 999121 ± 15.1147 ± 12.1NA ± NA137 ± 15.4142 ± 6.03114 ± 20165 ± 10.6159 ± 15.7128 ± 66.1
Total Antibody: Cycle 1121 ± 11.8122 ± 12.9152 ± 31.1148 ± 24.2153 ± 13118 ± 18.2102 ± 16.4129 ± 11.8111 ± 23.5114 ± 18.6152 ± 17.294.7 ± 34.2124 ± 11.8146 ± 16.4144 ± 18.3
Total Antibody: Cycle 3NA ± NA147 ± 25.1177 ± 26.6175 ± 22.7180 ± 4157.9 ± 238122 ± 20.9149 ± 15.5NA ± NA124 ± 3.32140 ± 19114 ± 17.8160 ± 23165 ± 17.4146 ± 44.2
SecondaryPK Parameter: Cmax of N2'-[4-[(3-carboxypropyl)Dithio]-4-methyl-1-oxo-2-sulfopentyl]-N2'-Deacetylmaytansine (DM4) and S-methyl DM4 (SmDM4)

Blood samples from participants were analyzed to characterize the PK of mirvetuximab soravtansine when administered in 3- or 4-week cycles. Results are reported in nanograms (ng)/mL.

Time frame:
Cycles 1 and 3: Day 1 (pre-infusion, within 10 minutes of end of infusion [EOI], and 6 hours post-infusion); Days 2 and 3 (24- and 48-hours post-infusion); Days 8 and 15 (additionally at Day 22 for Regimen C)
Reported as:
Geometric mean · ng/mL
PK Parameter: Cmax of N2'-[4-[(3-carboxypropyl)Dithio]-4-methyl-1-oxo-2-sulfopentyl]-N2'-Deacetylmaytansine (DM4) and S-methyl DM4 (SmDM4)
ng/mLRegimen A Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kgRegimen A Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kgRegimen A Dose Expansion Cohort 1: Bevacizumab-naïveRegimen A Dose Expansion Cohort 2: Bevacizumab Pre-treatedRegimen A Dose Expansion Cohort 3: Pt-agnostic:Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5Regimen B Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2Regimen C Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2Regimen D Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mgRegimen D Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mgRegimen D Dose Expansion: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mgRegimen E: Mirvetuximab Soravtansine + Bevacizumab + Carboplatin
DM4: Cycle 13.04 ± 21.84.71 ± 32.95.51 ± 35.86.32 ± 33.85.59 ± 37.52.96 ± 8.853.72 ± 28.76.4 ± 27.74.12 ± 47.53.93 ± 18.36.58 ± 86.44.54 ± 49.35.6 ± 31.25.27 ± 35.34.52 ± 38.4
DM4: Cycle 3NA ± NA5.06 ± 30.54.57 ± 27.36.16 ± 43.85.45 ± 69.13.06 ± 23.43.38 ± 155.66 ± 31.2NA ± NA5.1 ± 34.47.02 ± 70.83.91 ± 5.814.91 ± 37.34.95 ± 33.34.44 ± 25.7
S-methyl DM4: Cycle 13.61 ± 26.79.6 ± 65.511.5 ± 61.712.2 ± 68.912.2 ± 62.65.75 ± 56.37.91 ± 46.913 ± 37.57.23 ± 50.87.51 ± 58.111.9 ± 77.111.3 ± 56.617 ± 91.812.8 ± 63.68.64 ± 71.7
S-methyl DM4: Cycle 3NA ± NA12.3 ± 71.111.8 ± 55.712.2 ± 51.912.5 ± 89.23.21 ± 2206.79 ± 59.114.1 ± 43.9NA ± NA10.8 ± 55.717.6 ± 6316.2 ± 11.118 ± 52.913 ± 71.69.49 ± 104
SecondaryPK Parameter: Area Under the Time-Concentration Curve From Time 0 To Infinite Time (AUCinf) of Mirvetuximab Soravtansine and Total Antibody

Blood samples from participants were analyzed to characterize the PK of mirvetuximab soravtansine when administered in 3- or 4-week cycles. Results are reported in mg\*hours (h)/mL.

Time frame:
Cycles 1 and 3: Day 1 (pre-infusion, within 10 minutes of EOI, and 6 hours post-infusion); Days 2 and 3 (24- and 48-hours post-infusion); Days 8 and 15 (additionally at Day 22 for Regimen C)
Reported as:
Geometric mean · mg*h/mL
PK Parameter: Area Under the Time-Concentration Curve From Time 0 To Infinite Time (AUCinf) of Mirvetuximab Soravtansine and Total Antibody
mg*h/mLRegimen A Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kgRegimen A Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kgRegimen A Dose Expansion Cohort 1: Bevacizumab-naïveRegimen A Dose Expansion Cohort 2: Bevacizumab Pre-treatedRegimen A Dose Expansion Cohort 3: Pt-agnostic:Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5Regimen B Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2Regimen C Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2Regimen D Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mgRegimen D Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mgRegimen D Dose Expansion: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mgRegimen E: Mirvetuximab Soravtansine + Bevacizumab + Carboplatin
Mirvetuximab Soravtansine: Cycle 116.1 ± 2.3417 ± 13.918.6 ± 22.218.4 ± 22.117.5 ± 19.814.8 ± 13.811.3 ± 2316.3 ± 26.714 ± 23.815.2 ± 34.116.2 ± 33.112.1 ± 19.117 ± 30.516.9 ± 32.917.8 ± 26.3
Mirvetuximab Soravtansine: Cycle 3NA ± NA21.6 ± 37.222.7 ± 14.122.8 ± 24.922.3 ± 16.715.2 ± 22.117.9 ± 16.119.9 ± 26.5NA ± NA17.4 ± 19.416.4 ± 14.114.4 ± 32.120.2 ± 28.220.9 ± 30.819.7 ± 20
Total Antibody: Cycle 1NA ± NA20.6 ± 22.224.5 ± 31.423.5 ± 34.225.8 ± 2218 ± 22.213.3 ± 2921.6 ± 35.120.1 ± 5517.8 ± 73.524.8 ± 26.216.8 ± 16.318.4 ± 49.120 ± 44.625 ± 25.4
Total Antibody: Cycle 3NA ± NA24.2 ± 31.336.1 ± 2334.7 ± 49.339.2 ± 20.1NA ± NA—30 ± 26NA ± NANA ± NA29.1 ± 33.6NA ± NA20.1 ± 29.728.9 ± 55.235.8 ± 32.6
SecondaryPK Parameter: AUCinf of Intact DM4 and SmDM4

Blood samples from participants were analyzed to characterize the PK of mirvetuximab soravtansine when administered in 3- or 4-week cycles. Note that '9999' is used because AUCinf cannot be calculated for n\<3.

Time frame:
Cycles 1 and 3: Day 1 (pre-infusion, within 10 minutes of EOI, and 6 hours post-infusion); Days 2 and 3 (24- and 48-hours post-infusion); Days 8 and 15 (additionally at Day 22 for Regimen C)
Reported as:
Geometric mean · ng*h/mL
PK Parameter: AUCinf of Intact DM4 and SmDM4
ng*h/mLRegimen A Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kgRegimen A Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kgRegimen A Dose Expansion Cohort 1: Bevacizumab-naïveRegimen A Dose Expansion Cohort 2: Bevacizumab Pre-treatedRegimen A Dose Expansion Cohort 3: Pt-agnostic:Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5Regimen B Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2Regimen C Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2Regimen D Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mgRegimen D Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mgRegimen D Dose Expansion: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mgRegimen E: Mirvetuximab Soravtansine + Bevacizumab + Carboplatin
DM4: Cycle 1NA ± NA249 ± 12.6253 ± 28.2289 ± 30.9272 ± 28.4161 ± 15.2202 ± 21.6315 ± 55.6223 ± 64.8180 ± 19.7262 ± 49.6192 ± 33.2269 ± 17.7261 ± 31.6256 ± 40.7
DM4: Cycle 3NA ± NA282 ± 14.1263 ± 31.4315 ± 36.5285 ± 27.2146 ± 22180 ± 17.4295 ± 31.3NA ± NA200 ± 24.2289 ± 53.6163 ± 7.42245 ± 29.7260 ± 38.2243 ± 29.2
S-methyl DM4: Cycle 1NA ± NA1700 ± 51.51710 ± 73.21980 ± 60.72120 ± 62.11370 ± 49.2NA ± NA2160 ± 56.51510 ± 63.71660 ± 1191830 ± 72.22050 ± 502930 ± 91.32460 ± 70.81830 ± 61.2
S-methyl DM4: Cycle 3NA ± NA1730 ± 76.31620 ± 58.51930 ± 52.92120 ± 57.81130 ± 14.31600 ± 49.61600 ± 52.4NA ± NA1800 ± 80.82290 ± 70NA ± NA2280 ± 61.92080 ± 75.51550 ± 61.8
SecondaryPK Parameter: Terminal Half-Life (t½) of Mirvetuximab Soravtansine, Total Antibody, DM4, and SmDM4

Blood samples from participants were analyzed to characterize the PK of mirvetuximab soravtansine when administered in 3- or 4-week cycles. PK parameters were calculated using standard non-compartmental methods. The terminal t½ is an estimate (extrapolation) of the time it takes for the concentration or amount in the body of that drug to be reduced by exactly one-half (50%). If extrapolated AUC was greater than 20% (due to insufficient number of participants with data samples) the upper range of t½ was not reported.

Time frame:
Cycles 1 and 3: Day 1 (pre-infusion, within 10 minutes of EOI, and 6 hours post-infusion); Days 2 and 3 (24- and 48-hours post-infusion); Days 8 and 15 (up to 336 hours) (additionally at Day 22 for Regimen C)
Reported as:
Median · h
PK Parameter: Terminal Half-Life (t½) of Mirvetuximab Soravtansine, Total Antibody, DM4, and SmDM4
hRegimen A Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kgRegimen A Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kgRegimen A Dose Expansion Cohort 1: Bevacizumab-naïveRegimen A Dose Expansion Cohort 2: Bevacizumab Pre-treatedRegimen A Dose Expansion Cohort 3: Pt-agnostic:Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5Regimen B Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2Regimen C Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2Regimen D Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mgRegimen D Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mgRegimen D Dose Expansion: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mgRegimen E: Mirvetuximab Soravtansine + Bevacizumab + Carboplatin
Mirvetuximab Soravtansine: Cycle 1104 (104 to 143)123 (89.5 to 146)124 (76 to 154)121 (59.1 to 161)126 (82.1 to 168)117 (97.8 to 119)123 (97.7 to 152)128 (92.5 to 151)124 (114 to 176)148 (67.6 to 187)137 (86.2 to 156)120 (115 to 135)126 (70.3 to 184)126 (57.5 to 173)122 (85.9 to 172)
Mirvetuximab Soravtansine: Cycle 3NA (NA to NA)132 (93.7 to 157)132 (100 to 178)128 (65.9 to 181)130 (84.9 to 199)124 (119 to 146)124 (116 to 161)137 (108 to 165)NA (NA to NA)175 (76.6 to 237)119 (103 to 140)114 (97.8 to 118)132 (99.9 to 173)133 (62.5 to 192)140 (97.6 to 202)
Total Antibody: Cycle 1142 (107 to 226)206 (114 to 330)182 (87.9 to NA)221 (76.2 to NA)200 (119 to 315)189 (156 to 225)170 (165 to 286)208 (109 to 333)231 (200 to 299)282 (80.6 to NA)249 (182 to 314)184 (168 to 209)182 (68.9 to 269)196 (58 to NA)215 (111 to NA)
Total Antibody: Cycle 3NA (NA to NA)235 (165 to NA)214 (127 to NA)228 (86.8 to NA)216 (146 to NA)214 (143 to NA)290 (160 to NA)214 (163 to NA)NA (NA to NA)337 (94.5 to NA)230 (88.4 to NA)197 (135 to 278)269 (170 to NA)232 (70.3 to NA)251 (148 to NA)
DM4: Cycle 149.9 (40.5 to 121)74.4 (47.8 to 104)70.2 (47.2 to 99.7)61.9 (43.9 to 100)63.9 (40.1 to 124)59.4 (45 to 73.3)60.6 (40.4 to 124)52.4 (39.6 to 115)65.9 (48.6 to 120)55.8 (51.7 to 65.6)57.4 (43 to 91.4)46.4 (38 to 62.9)73.6 (42.8 to 131)59.4 (29.8 to 219)57.5 (39.9 to 116)
DM4: Cycle 3NA (NA to NA)83.8 (40.8 to 94.1)73.9 (32.8 to 102)71.1 (39.4 to 111)78.3 (19.1 to 109)68 (52.3 to 69.6)63.6 (59 to 111)74.1 (52.7 to 101)NA (NA to NA)96 (71.7 to 105)64.4 (45.5 to 115)46.5 (41.7 to 65.5)64.6 (53.3 to 109)64 (33 to 161)63 (45.2 to 109)
S-methyl DM4: Cycle 1NA (NA to NA)132 (97 to 178)126 (97.8 to 245)129 (81.7 to 217)139 (94.1 to 209)128 (96 to 151)NA (NA to NA)132 (99.2 to 165)168 (133 to 220)181 (156 to 285)154 (126 to NA)132 (106 to 169)134 (104 to 163)127 (73.4 to 253)126 (84.4 to 292)
S-methyl DM4: Cycle 3NA (NA to NA)128 (97.3 to 216)132 (94.8 to 172)126 (86.7 to 207)121 (79.1 to 196)140 (127 to 186)168 (107 to 233)124 (100 to 155)NA (NA to NA)182 (165 to 251)169 (105 to 213)171 (130 to 192)148 (120 to 158)140 (88.3 to 253)138 (84.9 to 275)
SecondaryPK Parameter: Clearance (CL) of Mirvetuximab Soravtansine and Total Antibody

Blood samples from participants were analyzed to characterize the PK of mirvetuximab soravtansine when administered in 3- or 4-week cycles.

Time frame:
Cycles 1 and 3: Day 1 (pre-infusion, within 10 minutes of EOI, and 6 hours post-infusion); Days 2 and 3 (24- and 48-hours post-infusion); Days 8 and 15 (additionally at Day 22 for Regimen C)
Reported as:
Geometric mean · mL/h
PK Parameter: Clearance (CL) of Mirvetuximab Soravtansine and Total Antibody
mL/hRegimen A Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kgRegimen A Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kgRegimen A Dose Expansion Cohort 1: Bevacizumab-naïveRegimen A Dose Expansion Cohort 2: Bevacizumab Pre-treatedRegimen A Dose Expansion Cohort 3: Pt-agnostic:Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5Regimen B Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2Regimen C Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2Regimen D Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mgRegimen D Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mgRegimen D Dose Expansion: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mgRegimen E: Mirvetuximab Soravtansine + Bevacizumab + Carboplatin
Mirvetuximab Soravtansine: Cycle 119.2 ± 18.822 ± 17.222 ± 29.120.9 ± 23.323.4 ± 23.819.9 ± 10.128.9 ± 1722 ± 26.121.2 ± 22.323.3 ± 38.624.5 ± 41.329.2 ± 17.123.9 ± 34.522.8 ± 34.522.1 ± 26.8
Mirvetuximab Soravtansine: Cycle 3NA ± NA16.9 ± 34.417.7 ± 2316.5 ± 26.918.3 ± 21.419.3 ± 17.918.2 ± 1417.2 ± 24.9NA ± NA20.3 ± 23.924.3 ± 21.426.4 ± 2518.3 ± 36.817.7 ± 35.619.2 ± 23.6
Total Antibody: Cycle 1NA ± NA18 ± 23.817.5 ± 36.516.7 ± 33.916.3 ± 25.916.3 ± 19.824.5 ± 24.616.6 ± 36.114.7 ± 47.119.3 ± 83.415.7 ± 34.621.1 ± 15.222.6 ± 49.220 ± 44.716.1 ± 26.7
Total Antibody: Cycle 3NA ± NA15 ± 34.311.7 ± 27.311.2 ± 43.310.7 ± 26NA ± NA—11.1 ± 20.5NA ± NANA ± NA13.9 ± 40.5NA ± NA16.4 ± 63.912.9 ± 57.59.69 ± 38.1
SecondaryPK Parameter: CL of DM4 and SmDM4

Blood samples from participants were analyzed to characterize the PK of mirvetuximab soravtansine when administered in 3- or 4-week cycles.

Time frame:
Cycles 1 and 3: Day 1 (pre-infusion, within 10 minutes of EOI, and 6 hours post-infusion); Days 2 and 3 (24- and 48-hours post-infusion); Days 8 and 15 (additionally at Day 22 for Regimen C)
Reported as:
Geometric mean · L/h
PK Parameter: CL of DM4 and SmDM4
L/hRegimen A Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kgRegimen A Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kgRegimen A Dose Expansion Cohort 1: Bevacizumab-naïveRegimen A Dose Expansion Cohort 2: Bevacizumab Pre-treatedRegimen A Dose Expansion Cohort 3: Pt-agnostic:Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5Regimen B Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2Regimen C Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2Regimen D Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mgRegimen D Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mgRegimen D Dose Expansion: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mgRegimen E: Mirvetuximab Soravtansine + Bevacizumab + Carboplatin
DM4: Cycle 1NA ± NA29 ± 19.330.9 ± 31.525.2 ± 36.628.6 ± 33.335 ± 14.630.7 ± 26.821.8 ± 64.725.1 ± 59.337.4 ± 28.328.2 ± 52.235.5 ± 57.228.8 ± 30.727.7 ± 27.529.1 ± 40.4
DM4: Cycle 3NA ± NA23.5 ± 26.428.9 ± 3322.7 ± 39.727.2 ± 35.538.6 ± 1634.5 ± 23.422.1 ± 45.8NA ± NA33.5 ± 41.526.6 ± 54.344.6 ± 22.328.8 ± 44.426.7 ± 31.829.5 ± 31.5
S-methyl DM4: Cycle 1NA ± NA4.49 ± 40.24.77 ± 61.13.84 ± 57.93.82 ± 60.84.39 ± 52NA ± NA3.35 ± 70.63.9 ± 59.64.21 ± 1194.17 ± 62.83.42 ± 732.78 ± 91.83.06 ± 63.24.25 ± 57.1
S-methyl DM4: Cycle 3NA ± NA4.18 ± 66.44.97 ± 48.63.84 ± 50.53.87 ± 52.75.19 ± 20.34.19 ± 48.34.26 ± 59NA ± NA3.9 ± 83.43.45 ± 56.3NA ± NA3.22 ± 81.93.57 ± 63.94.78 ± 60.4
SecondaryPK Parameter: Volume of Distribution at Steady State (Vss) of Mirvetuximab Soravtansine, Total Antibody, DM4, and SmDM4

Blood samples from participants were analyzed to characterize PK when administered in 3- or 4-week cycles.

Time frame:
Cycles 1 and 3: Day 1 (pre-infusion, within 10 minutes of EOI, and 6 hours post-infusion); Days 2 and 3 (24- and 48-hours post-infusion); Days 8 and 15 (additionally at Day 22 for Regimen C)
Reported as:
Geometric mean · L
PK Parameter: Volume of Distribution at Steady State (Vss) of Mirvetuximab Soravtansine, Total Antibody, DM4, and SmDM4
LRegimen A Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kgRegimen A Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kgRegimen A Dose Expansion Cohort 1: Bevacizumab-naïveRegimen A Dose Expansion Cohort 2: Bevacizumab Pre-treatedRegimen A Dose Expansion Cohort 3: Pt-agnostic:Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5Regimen B Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2Regimen C Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2Regimen D Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mgRegimen D Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mgRegimen D Dose Expansion: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mgRegimen E: Mirvetuximab Soravtansine + Bevacizumab + Carboplatin
Mirvetuximab Soravtansine Cycle 12.93 ± 18.23.63 ± 12.43.54 ± 19.73.31 ± 18.53.87 ± 25.23.23 ± 7.044.29 ± 11.93.52 ± 23.33.69 ± 17.93.8 ± 10.73.88 ± 24.14.58 ± 20.93.78 ± 21.83.59 ± 23.13.73 ± 23
Mirvetuximab Soravtansine Cycle 3NA ± NA3.21 ± 14.13.25 ± 13.22.83 ± 23.33.23 ± 23.43.37 ± 13.33.4 ± 15.73.13 ± 12.5NA ± NA3.78 ± 16.63.98 ± 193.94 ± 15.43.28 ± 313.1 ± 25.83.51 ± 21.6
Total Antibody Cycle 1NA ± NA4.38 ± 16.14.05 ± 22.73.9 ± 34.94.06 ± 23.94.03 ± 28.15.67 ± 10.74.27 ± 24.44.48 ± 39.25.01 ± 1.584.09 ± 17.25.33 ± 18.74.69 ± 234.09 ± 30.14.21 ± 25.6
Total Antibody Cycle 3NA ± NA3.74 ± 23.73.17 ± 17.22.97 ± 34.62.95 ± 24.4NA ± NA—3.09 ± 8.55NA ± NANA ± NA3.76 ± 49.6NA ± NA4.01 ± 57.53.28 ± 30.52.9 ± 25.4
DM4 Cycle 1NA ± NA2590 ± 23.82490 ± 31.42010 ± 38.62240 ± 40.42670 ± 20.92580 ± 59.41720 ± 361880 ± 51.62730 ± 26.52010 ± 53.52100 ± 80.92410 ± 52.52060 ± 31.12350 ± 45.1
DM4 Cycle 3NA ± NA2190 ± 20.72480 ± 24.31990 ± 43.72370 ± 35.93030 ± 7.843160 ± 7.051900 ± 55.6NA ± NA3300 ± 38.42140 ± 35.92930 ± 22.92450 ± 53.62270 ± 32.82450 ± 29.1
SmDM4 Cycle 1NA ± NA911 ± 57.3900 ± 67.1731 ± 69.3751 ± 66.7932 ± 63.7NA ± NA652 ± 65832 ± 61.61100 ± 114855 ± 66.3695 ± 81.2547 ± 97.6592 ± 66.4840 ± 65.1
SmDM4 Cycle 3NA ± NA761 ± 53.6878 ± 48.6698 ± 51.8696 ± 511100 ± 1.87833 ± 24.5754 ± 60.7NA ± NA947 ± 82.5773 ± 64.7NA ± NA621 ± 76.2709 ± 59.1891 ± 67.2
SecondaryPK Parameter: Time to Reach Cmax (Tmax) of Mirvetuximab Soravtansine, Total Antibody, DM4, and SmDM4

Blood samples from participants were analyzed to characterize the PK of mirvetuximab soravtansine when administered in 3- or 4-week cycles. PK parameters were derived using non-compartmental PK analysis.

Time frame:
Cycles 1 and 3: Day 1 (pre-infusion, within 10 minutes of EOI, and 6 hours post-infusion); Days 2 and 3 (24- and 48-hours post-infusion); Days 8 and 15 (up to 336 hours) (additionally at Day 22 for Regimen C)
Reported as:
Median · h
PK Parameter: Time to Reach Cmax (Tmax) of Mirvetuximab Soravtansine, Total Antibody, DM4, and SmDM4
hRegimen A Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kgRegimen A Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kgRegimen A Dose Expansion Cohort 1: Bevacizumab-naïveRegimen A Dose Expansion Cohort 2: Bevacizumab Pre-treatedRegimen A Dose Expansion Cohort 3: Pt-agnostic:Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5Regimen B Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2Regimen C Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2Regimen D Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mgRegimen D Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mgRegimen D Dose Expansion: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mgRegimen E: Mirvetuximab Soravtansine + Bevacizumab + Carboplatin
Mirvetuximab Soravtansine: Cycle 11.75 (1.52 to 1.85)1.9 (1.32 to 7.48)2.1 (1.63 to 7.8)1.92 (1.62 to 8.08)2.06 (1.42 to 24)1.68 (1.63 to 1.72)1.96 (1.72 to 7.78)1.86 (1.5 to 7.57)4.28 (1.22 to 7.62)1.73 (1.45 to 7.08)5.98 (1.73 to 8.05)2 (1.67 to 7.57)2.14 (1.87 to 7.72)2.12 (1.62 to 8.23)2.07 (1.47 to 8.22)
Mirvetuximab Soravtansine: Cycle 3NA (NA to NA)3.88 (0.967 to NA)3.46 (1.17 to 7.5)2.24 (1.02 to 7.37)1.49 (1.08 to NA)4.06 (0.95 to NA)1.02 (0.95 to 5.35)1.48 (1.07 to 5.97)NA (NA to NA)4.04 (1.2 to 7)6.08 (1.15 to 7.33)1.45 (1.17 to 22)1.26 (1.15 to 7.1)1.5 (0.95 to 25.6)6.98 (0.95 to NA)
Total Antibody: Cycle 11.75 (1.52 to 5.52)1.9 (1.32 to 7.75)2.1 (1.63 to 25.6)1.9 (1.62 to 48.2)2.05 (1.48 to 9)1.68 (1.63 to 24.1)4.09 (1.72 to 7.78)1.88 (1.5 to 7.55)3.84 (1.63 to 6.75)1.87 (1.45 to 7.53)5.98 (1.67 to 25)4.82 (1.67 to 7.87)2.25 (1.88 to 48.9)2.08 (1.43 to 8.05)2.2 (1.13 to NA)
Total Antibody: Cycle 3NA (NA to NA)3.88 (0.967 to 48.9)3.68 (1.08 to 25.2)2.24 (1.02 to 27.2)1.49 (1.08 to NA)6.91 (1.02 to NA)1.03 (0.95 to 7.05)1.48 (1.17 to 5.83)NA (NA to NA)1.23 (1.05 to 6.83)7.12 (6.08 to 49.6)7.1 (1.05 to 48.7)3.7 (1.15 to 24)1.63 (0.95 to 25.1)3.03 (0.967 to NA)
DM4: Cycle 17.2 (5.52 to 7.27)7.5 (1.32 to 26.4)7.78 (1.83 to 8.58)7.63 (0 to 22.4)7.58 (1.67 to 24)7.4 (1.72 to 7.6)7.56 (6 to 7.78)7.34 (5.87 to 21.5)7.12 (5.87 to 7.62)7.32 (6 to 7.53)5.98 (1.67 to 8.05)7.62 (7.53 to 7.87)7.7 (2.25 to 8.22)7.58 (1.73 to 24)7.67 (1.58 to 8.22)
DM4: Cycle 3NA (NA to NA)7 (1.25 to 7.75)7.06 (1.25 to 7.63)6.94 (1.08 to 7.82)6.96 (1.1 to NA)6.99 (6.82 to NA)6.96 (5.35 to 7.05)6.08 (5.03 to 7.77)NA (NA to NA)6.89 (1.2 to 7)7.02 (6.08 to 7.33)7.1 (1.05 to 7.6)7.08 (1.33 to 7.45)7.03 (0.95 to 24.8)7.13 (0.95 to NA)
S-methyl DM4: Cycle 123.8 (7.2 to 119)23.9 (5.87 to 170)7.83 (5.87 to 46.7)7.83 (5.68 to 166)8.26 (6.05 to 170)48.2 (24.6 to 169)108 (25.4 to 170)7.34 (5.87 to 163)23.8 (6.75 to 23.9)23.8 (7.53 to 24.4)7.7 (5.98 to 50.4)7.72 (7.53 to 49.6)7.84 (6.17 to 167)8 (7.18 to 171)8.15 (6.93 to 167)
S-methyl DM4: Cycle 3NA (NA to NA)7.01 (5.83 to 24.6)7.17 (5.83 to 47.7)7.11 (5.67 to 48.7)7.41 (6.02 to NA)6.99 (6.82 to NA)15.1 (5.35 to 47.6)6.08 (5.03 to 21.3)NA (NA to NA)7.04 (6.83 to 47.2)7.02 (6.08 to 7.33)7.1 (6.87 to 7.6)7.08 (6.08 to 7.45)7.12 (0.95 to 47.3)7.22 (0.95 to NA)
SecondaryPlasma Concentration of Bevacizumab

Blood samples from participants at the end of infusion were analyzed to characterize the PK of mirvetuximab soravtansine when administered in 3- or 4-week cycles.

Time frame:
At end of infusion (EOI) of Cycle 1; and at pre-infusion and EOI of Cycles 2 to 6
Reported as:
Geometric mean · ug/mL
Plasma Concentration of Bevacizumab
ug/mLRegimen A Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kgRegimen A Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kgRegimen A Dose Expansion Cohort 1: Bevacizumab-naïveRegimen A Dose Expansion Cohort 2: Bevacizumab Pre-treatedRegimen A Dose Expansion Cohort 3: Pt-agnostic:Regimen E: Mirvetuximab Soravtansine + Bevacizumab + Carboplatin
Cycle 1 EOI368 ± 20.2352 ± 31.9406 ± 22.3430 ± 19.3448 ± 23.2413 ± 23.9
Cycle 2 Pre-infusion69.3 ± 3766 ± 35.490.6 ± 57.887.5 ± 37.488.1 ± 3592.5 ± 39.9
Cycle 2 EOINA ± NA477 ± 23.8429 ± 38.2528 ± 20.8559 ± 28.4473 ± 44.6
Cycle 3 Pre-infusionNA ± NA79.9 ± 52.9132 ± 17117 ± 39.3118 ± 51.2127 ± 45.8
Cycle 3 EOINA ± NA408 ± 59.2540 ± 23.6556 ± 17.8616 ± 22.1531 ± 33.1
Cycle 4 Pre-infusionNA ± NA133 ± 24.1134 ± 51.1141 ± 49.4123 ± 78.2132 ± 92.9
Cycle 4 EOINA ± NA537 ± 25.2539 ± 20.7505 ± 39.1584 ± 35.7485 ± 128
Cycle 5 Pre-infusionNA ± NA134 ± 18.3163 ± 28.9151 ± 36.1137 ± 61153 ± 51
Cycle 5 EOINA ± NA583 ± 31.1565 ± 19.1587 ± 20.3558 ± 80.6547 ± 24.1
Cycle 6 Pre-infusionNA ± NA80.7 ± 96.8191 ± 27.6149 ± 37.8166 ± 29.6170 ± 51.5
Cycle 6 EOINA ± NA513 ± 29.1574 ± 26.2559 ± 23.9654 ± 24.6525 ± 39.8
SecondaryPlasma Concentration of Carboplatin

Blood samples from participants at the end of infusion were analyzed to characterize the PK of mirvetuximab soravtansine when administered in 3- or 4-week cycles.

Time frame:
At end of infusion, 6 and 24 hours post-infusion of Cycle 1; and at pre-infusion and end of infusion of Cycles 2, 4, 5 and 6; at pre-infusion, end of infusion and 6 and 24 hours post-infusion of Cycle 3
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Carboplatin
ng/mLRegimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5Regimen B Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5Regimen E: Mirvetuximab Soravtansine + Bevacizumab + Carboplatin
Cycle 1: EOI10300 ± 11.31060 ± 35.213900 ± 1911800 ± 25.6
Cycle 1: 6 hours post-infusion2890 ± 45.63790 ± 10.33120 ± 151—
Cycle 1 24 hours post-infusion719 ± 4.77913 ± 19.71030 ± 43.8817 ± 35
Cycle 2: Pre-infusion124 ± 14.8142 ± 21.7158 ± 13.5170 ± 79.2
Cycle 2: EOI10800 ± 2211600 ± 18.511700 ± 80.911000 ± 146
Cycle 3: Pre-infusionNA ± NA245 ± 34.6173 ± 35.9203 ± 28.2
Cycle 3: EOINA ± NA4170 ± 94612100 ± 28.912300 ± 26.9
Cycle 3: 6 hours post-infusion1140 ± 4123890 ± 29.91630 ± 238—
Cycle 3: 24 hours post-infusionNA ± NA1330 ± 27.31270 ± 41.31440 ± 49
Cycle 4: Pre-infusion220 ± 31.8243 ± 59.1214 ± 20.6250 ± 39.9
Cycle 4: EOI8230 ± 43.9NA ± NA214 ± 20.612500 ± 29.9
Cycle 5: Pre-infusion199 ± 41.8NA ± NA194 ± 37.9270 ± 43
Cycle 5: EOI10900 ± 36.9NA ± NA13800 ± 31.811200 ± 88.1
Cycle 6: Pre-infusion251 ± 20.2NA ± NA234 ± 24.6271 ± 45.4
Cycle 6: EOI12100 ± 32.5NA ± NA12100 ± 32.110700 ± 77.9
SecondaryPlasma Concentration of Pegylated Liposomal Doxorubicin

Blood samples from participants at the end of infusion were analyzed to characterize the PK of mirvetuximab soravtansine when administered in 3- or 4-week cycles.

Time frame:
At end of infusion of Cycle 1; and at pre-infusion and end of infusion of Cycles 2 to 6
Reported as:
Geometric mean · ng/mL
Plasma Concentration of Pegylated Liposomal Doxorubicin
ng/mLRegimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2Regimen C Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2
Cycle 1: EOI18700 ± 8.7224400 ± 14.326400 ± 7.85
Cycle 2: Pre-infusion—NA ± NA226 ± 44.9
Cycle 2: EOI17300 ± 17.125700 ± 6.8826100 ± 12.1
Cycle 3: Pre-infusionNA ± NANA ± NA228 ± 63
Cycle 3: EOINA ± NA26200 ± 12.826200 ± 14.3
Cycle 4: Pre-infusion—NA ± NA151 ± 54.2
Cycle 4: EOINA ± NA24300 ± 24.124400 ± 15.4
Cycle 5: Pre-infusion—NA ± NA177 ± 81.1
Cycle 5: EOINA ± NA23700 ± 17.125000 ± 11.3
Cycle 6: Pre-infusion—NA ± NA157 ± 134
Cycle 6: EOINA ± NA22900 ± 13.324600 ± 14.7
SecondaryImmunogenicity: Number of Participants With Anti-Drug Antibody (ADA) Response to Mirvetuximab Soravtansine

Blood samples were collected to measure the presence of ADAs for mirvetuximab soravtansine. Seronegative is defined as a participant that tests negative at all visits. Treatment-emergent ADA is defined as a participant that is seronegative prior to dosing on Day 1 of Cycle 1 and tests positive in both screening and confirmatory assays at one or more subsequent visits. Treatment-unaffected ADA is defined as a participant test positive in both screening and confirmatory assays prior to dosing on Day 1 of Cycle 1 with a post-dose titer increase of less than or equal to 4-fold (based on a 2-fold sample dilution). Treatment-boosted ADA is defined as a participant test positive in both screening and confirmatory assays prior to dosing on Day 1 of Cycle 1 with a post-dose titer increase of more than a 4-fold increase (based on a 2-fold sample dilution).

Time frame:
From first dose of study drug up to 30 days after last dose of study drug (maximum exposure: 283.3 weeks)
Reported as:
Count of participants · Participants
Immunogenicity: Number of Participants With Anti-Drug Antibody (ADA) Response to Mirvetuximab Soravtansine
ParticipantsDose Escalation PhaseDose Expansion Phase
Seronegative51175
Treatment-emergent ADA311
Treatment-unaffected ADA711
Treatment-boosted ADA15

Adverse events

Collected over From first dose of study drug up to 30 days after last dose of study drug (maximum exposure: 238.3 weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kg0/3 (0%)2/3 (66.7%)3/3 (100%)
Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kg5/126 (4%)49/126 (38.9%)125/126 (99.2%)
Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC40/4 (0%)2/4 (50%)4/4 (100%)
Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC50/4 (0%)4/4 (100%)4/4 (100%)
Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC50/10 (0%)3/10 (30%)10/10 (100%)
Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^20/4 (0%)1/4 (25%)4/4 (100%)
Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^20/5 (0%)2/5 (40%)4/5 (80%)
Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^20/7 (0%)3/7 (42.9%)7/7 (100%)
Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mg0/4 (0%)2/4 (50%)4/4 (100%)
Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg4/56 (7.1%)25/56 (44.6%)56/56 (100%)
Mirvetuximab Soravtansine + Bevacizumab + Carboplatin2/41 (4.9%)17/41 (41.5%)41/41 (100%)
Most frequent serious events
Showing 10 of 87
Most frequent serious events
EventMirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kgMirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kgMirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mgMirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mgMirvetuximab Soravtansine + Bevacizumab + Carboplatin
PneumonitisRespiratory, thoracic and mediastinal disorders0/33/1260/43/40/100/40/51/70/44/561/41
Small intestinal obstructionGastrointestinal disorders1/37/1260/40/41/101/40/51/71/45/562/41
VomitingGastrointestinal disorders1/30/1260/40/40/100/40/51/70/43/561/41
HeadacheNervous system disorders1/32/1260/40/40/100/40/50/70/40/560/41
HypertensionVascular disorders1/30/1260/40/40/100/40/50/70/40/560/41
Malignant gastrointestinal obstructionGastrointestinal disorders0/30/1260/40/40/100/40/50/71/40/560/41
Vaginal haemorrhageReproductive system and breast disorders0/32/1260/41/40/100/40/50/70/40/560/41
Flank painMusculoskeletal and connective tissue disorders0/30/1261/40/40/100/40/50/70/40/560/41
DehydrationMetabolism and nutrition disorders0/30/1261/40/40/100/40/50/70/40/560/41
Clostridium difficile colitisInfections and infestations0/30/1260/40/40/100/41/50/70/40/560/41
Most frequent other events
Showing 10 of 600
Most frequent other events
EventMirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kgMirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kgMirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mgMirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mgMirvetuximab Soravtansine + Bevacizumab + Carboplatin
DiarrhoeaGastrointestinal disorders1/385/1264/43/45/103/44/54/72/432/5634/41
NauseaGastrointestinal disorders2/373/1261/42/410/101/44/56/73/430/5633/41
FatigueGeneral disorders1/367/1262/42/47/101/44/54/74/428/5630/41
HypomagnesaemiaMetabolism and nutrition disorders1/327/1264/41/42/100/40/50/71/46/569/41
ConstipationGastrointestinal disorders1/333/1260/41/44/102/44/52/72/416/5612/41
Vision blurredEye disorders2/371/1263/43/46/100/43/53/72/426/5631/41
DyspnoeaRespiratory, thoracic and mediastinal disorders1/325/1261/43/44/100/42/53/70/412/5612/41
Decreased appetiteMetabolism and nutrition disorders1/347/1260/43/43/100/40/53/72/415/5618/41
HypokalaemiaMetabolism and nutrition disorders0/313/1263/42/43/102/40/53/71/412/564/41
ThrombocytopeniaBlood and lymphatic system disorders0/337/1262/43/46/100/41/52/70/44/5629/41

Baseline characteristics

All participants who were enrolled and received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Regimen A Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kgRegimen A Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kgRegimen A Dose Expansion Cohort 1: Bevacizumab-naïveRegimen A Dose Expansion Cohort 2: Bevacizumab Pre-treatedRegimen A Dose Expansion Cohort 3: Pt-agnostic:Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5Regimen B Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2Regimen C Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2Regimen D Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mgRegimen D Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mgRegimen D Dose Expansion: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mgRegimen E: Mirvetuximab Soravtansine + Bevacizumab + CarboplatinTotal
Mean64.3 ± 11.8565.5 ± 8.4362.2 ± 7.4061.4 ± 9.9961.4 ± 9.8759.3 ± 9.1467.0 ± 7.0766.0 ± 10.3359.5 ± 12.0765.2 ± 4.6660.6 ± 5.3558.3 ± 6.1863.5 ± 10.8161.1 ± 8.6463.8 ± 9.4062.3 ± 9.16
Sex: Female, Male
Sex: Female, Male(Participants)Regimen A Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kgRegimen A Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kgRegimen A Dose Expansion Cohort 1: Bevacizumab-naïveRegimen A Dose Expansion Cohort 2: Bevacizumab Pre-treatedRegimen A Dose Expansion Cohort 3: Pt-agnostic:Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5Regimen B Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2Regimen C Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2Regimen D Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mgRegimen D Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mgRegimen D Dose Expansion: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mgRegimen E: Mirvetuximab Soravtansine + Bevacizumab + CarboplatinTotal
Female31121346044104574104641264
Male0000000000000000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Regimen A Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kgRegimen A Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kgRegimen A Dose Expansion Cohort 1: Bevacizumab-naïveRegimen A Dose Expansion Cohort 2: Bevacizumab Pre-treatedRegimen A Dose Expansion Cohort 3: Pt-agnostic:Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5Regimen B Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2Regimen C Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2Regimen D Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mgRegimen D Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mgRegimen D Dose Expansion: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mgRegimen E: Mirvetuximab Soravtansine + Bevacizumab + CarboplatinTotal
Hispanic or Latino0001200001000116
Not Hispanic or Latino3112132584494474104539255
Unknown or Not Reported0001000100000013
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Regimen A Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kgRegimen A Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kgRegimen A Dose Expansion Cohort 1: Bevacizumab-naïveRegimen A Dose Expansion Cohort 2: Bevacizumab Pre-treatedRegimen A Dose Expansion Cohort 3: Pt-agnostic:Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4Regimen B Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5Regimen B Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2Regimen C Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2Regimen C Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2Regimen D Dose Escalation: Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mgRegimen D Dose Escalation: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mgRegimen D Dose Expansion: Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mgRegimen E: Mirvetuximab Soravtansine + Bevacizumab + CarboplatinTotal
American Indian or Alaska Native0001100000000002
Asian0000300000000227
Native Hawaiian or Other Pacific Islander0000000000000000
Black or African American0001000000000102
White31021325344104574104339249
More than one race0000000000000000
Unknown or Not Reported0100300000000004
08

Study locations

12 sites
  • University of California at Los Angeles
    Los Angeles, California, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • City of Hope
    Reno, Nevada, United States
  • The Ohio State University
    Hilliard, Ohio 43026, United States
  • Peggy and Charles Stephenson Oklahoma Cancer Center
    Oklahoma City, Oklahoma 73104, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • Universitaire Ziekenhuizen (UZ) Leuven - Gasthuisberg - Leuvens Kankerinstituut
    Leuven, 3000, Belgium
  • Centre Hospitalier de l'universite de Montreal (CHUM)
    Montreal, Canada
  • McGill University Health Center
    Montreal, Canada
  • Hospital Vall D'Hebron
    Barcelona, Spain
  • MD Anderson
    Madrid, 28033, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in Mar 2021, 60 months.

Results were first posted in Feb 2024, 2 years 11 months after primary completion. A results delay was requested in Dec 2021.

Of 26 phase 1/2 interventional studies under Carcinoma, Ovarian Epithelial, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 74. This study's 60 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2015
First posted
Nov 17, 2015
StartActual
Mar 2, 2016
Primary completionActual
Mar 12, 2021
CompletionActual
Mar 12, 2021
Results delay requested
Dec 13, 2021
Results first posted
Feb 14, 2024
Last update
Jun 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02606305
Lead sponsor
ImmunoGen, Inc.
Responsible party
Sponsor
First posted
Nov 17, 2015
Start date
Mar 2, 2016
Primary completion
Mar 12, 2021
Completion
Mar 12, 2021
Results posted
Feb 14, 2024
Last update
Jun 14, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mirvetuximab soravtansine

Start the discussion